Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hentig

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
The Journal of Antimicrobial Chemotherapy|August 30, 2008
Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitorsNils von Hentig, Ann-Kristin Förster, Karina Kuczka, et al.
The Journal of Antimicrobial Chemotherapy|September 25, 2009
Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patientsM Bickel, A Bodtländer, G K Knecht, et al.
Antiviral Therapy|February 7, 2009
Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancyNils von Hentig, Gabi Nisius, Tessa Lennemann, et al.
AIDS (London, England)|April 20, 2004
Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavirChristoph Stephan, Nils von Hentig, Irene Kourbeti, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2011
Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategiesLaura Dickinson, Marta Boffito, David Back, et al.
Therapeutic Drug Monitoring|March 18, 2014
Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairmentPavel Khaykin, Peter Kotzerke, Christoph Stephan, et al.
Antimicrobial Agents and Chemotherapy|February 14, 2007
Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimenNils von Hentig, Axel Müller, Carsten Rottmann, et al.
British Journal of Clinical Pharmacology|October 26, 2006
A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancyNils von Hentig, Amina Carlebach, Peter Gute, et al.
European Journal of Medical Research|December 17, 2005
Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected childrenMarkus B Funk, G Notheis, T Schuster, et al.
Medical Microbiology and Immunology|September 18, 2012
Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapyChristoph Stephan, Valentin Bartha, Eva Herrmann, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
The Journal of Antimicrobial Chemotherapy|August 30, 2008
Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitorsNils von Hentig, Ann-Kristin Förster, Karina Kuczka, et al.
The Journal of Antimicrobial Chemotherapy|September 25, 2009
Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patientsM Bickel, A Bodtländer, G K Knecht, et al.
Antiviral Therapy|February 7, 2009
Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancyNils von Hentig, Gabi Nisius, Tessa Lennemann, et al.
AIDS (London, England)|April 20, 2004
Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavirChristoph Stephan, Nils von Hentig, Irene Kourbeti, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2011
Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategiesLaura Dickinson, Marta Boffito, David Back, et al.
Therapeutic Drug Monitoring|March 18, 2014
Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairmentPavel Khaykin, Peter Kotzerke, Christoph Stephan, et al.
Antimicrobial Agents and Chemotherapy|February 14, 2007
Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimenNils von Hentig, Axel Müller, Carsten Rottmann, et al.
British Journal of Clinical Pharmacology|October 26, 2006
A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancyNils von Hentig, Amina Carlebach, Peter Gute, et al.
European Journal of Medical Research|December 17, 2005
Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected childrenMarkus B Funk, G Notheis, T Schuster, et al.
Medical Microbiology and Immunology|September 18, 2012
Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapyChristoph Stephan, Valentin Bartha, Eva Herrmann, et al.
Pageof 6